Evidence map›Paper›PMID 24065619›Full record

ArticleCytotechnology2014

Evaluation of YO-PRO-1 as an early marker of apoptosis following radiofrequency ablation of colon cancer liver metastases.

Sho Fujisawa, Yevgeniy Romin, Afsar Barlas, Lydia M Petrovic, Mesruh Turkekul, Ning Fan, Ke Xu, Alessandra R Garcia, Sebastien Monette, David S Klimstra and 4 more

Open access · bronzeAbstract read
In one paragraph

Article in Cytotechnology, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 35 papers.

0numbers the graph read from it
0cells of the map it votes in
35citing papers in PubMed
2.4field-weighted citation impact, top 12% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

35 citing papers in PubMed, 59 citations in OpenAlex.

  1. International journal of molecular sciences · 2026
    Article
  2. Article
  3. Techniques to Determine Mammalian Sperm Capacitation.Methods in molecular biology (Clifton, N.J.) · 2025
    Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Roles of viable but non-culturable state in the survival ofFrontiers in cellular and infection microbiology · 2023
    Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. First Report of Genetic Variability ofPathogens (Basel, Switzerland) · 2021
    Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors at 2 institutions in 1 country.

Sho FujisawaMolecular Cytology Core Facility, Memorial Sloan-Kettering Cancer, New York, NY, USA.
Yevgeniy Romin
Afsar Barlas
Lydia M Petrovic
Mesruh Turkekul
Ning Fan
Ke Xu
Alessandra R Garcia
Sebastien Monette
David S Klimstra
Joseph P Erinjeri
Stephen B Solomon
Katia Manova-Todorova
Constantinos T Sofocleous
Memorial Sloan Kettering Cancer Center · USSouthern California University for Professional Studies · US

Funding

X-RAY CRYSTALLOGRAPHYP30CA008748 · NCI · SLOAN-KETTERING INSTITUTE FOR CANCER RES · PI Nicholas D Socci · 1985 to 2026
$347.4M
Histopathologic and Immunohistochemical Features of Tissue Adherent to the ElectrR21CA131763 · NCI · SLOAN-KETTERING INST CAN RESEARCH · PI SOFOCLEOUS, CONSTANTINOS THASOS · 2009 to 2011
$453k
NCI NIH HHS P30 CA008748NCI NIH HHS R21 CA131763
6 · The paper itself

Abstract

unlabelledRadiofrequency (RF) ablation (RFA) is a minimally invasive treatment for colorectal-cancer liver metastases (CLM) in selected nonsurgical patients. Unlike surgical resection, RFA is not followed by routine pathological examination of the target tumor and the surrounding liver tissue. The aim of this study was the evaluation of apoptotic events after RFA. Specifically, we evaluated YO-PRO-1 (YP1), a green fluorescent DNA marker for cells with compromised plasma membrane, as a potential, early marker of cell death. YP1 was applied on liver tissue adherent on the RF electrode used for CLM ablation, as well as on biopsy samples from the center and the margin of the ablation zone as depicted by dynamic CT immediately after RFA. Normal pig and mouse liver tissues were used for comparison. The same samples were also immunostained for fragmented DNA (TUNEL assay) and for active mitochondria (anti-OxPhos antibody). YP1 was also used simultaneously with propidium iodine (PI) to stain mouse liver and samples from ablated CLM. Following RFA of human CLM, more than 90 % of cells were positive for YP1. In nonablated, dissected pig and mouse liver however, we found similar YP1 signals (93.1 % and 65 %, respectively). In samples of intact mouse liver parenchyma, there was a significantly smaller proportion of YP1 positive cells (22.7 %). YP1 and PI staining was similar for ablated CLM. However in dissected normal mouse liver there was initial YP1 positivity and complete absence of the PI signal and only later there was PI signal.

conclusionThis is the first time that YP1 was applied in liver parenchymal tissue (rather than cell culture). The results suggest that YP1 is a very sensitive marker of early cellular events reflecting an early and widespread plasma membrane injury that allows YP1 penetration into the cells.

Identifiers

PMID24065619
PMCPMC3918265
OpenAlexW2066779145

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.